Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$12.00 USD
-0.35 (-2.83%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $12.17 +0.17 (1.42%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
OCUL 12.00 -0.35(-2.83%)
Will OCUL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OCUL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCUL
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
OCUL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Other News for OCUL
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and ...
Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight
Q2 2025 Ocular Therapeutix Inc Earnings Call Transcript
Ocular Therapeutix (OCUL) Financial Outlook Remains Robust Through 2028